Selective β-esterification of BOC-L-aspartic acid to the 4-benzyl ester is the first downstream unit operation where the unprotected side-chain carboxyl is differentiated from the α-position. On a production-scale glass-lined reactor, BOC-L-aspartic acid is charged at 1.0 mol equiv, benzyl alcohol at 1.1–1.3 mol equiv, dicyclohexylcarbodiimide at 1.05–1.2 mol equiv, and 4-(dimethylamino)pyridine at 0.05–0.1 mol equiv in dichloromethane. The jacket setpoint is held between 0 °C and 5 °C for the first 4 h to reduce N-acylurea rearrangement, then allowed to rise to 20 °C for the remaining 4–6 h. The reaction mass is washed with 5% w/w citric acid and 0.1 M sodium bicarbonate; dicyclohexylurea is removed by filtration through a 0.45 μm PTFE membrane. After solvent exchange to ethyl acetate/n-heptane 1:3 v/v, recrystallization yields the 4-benzyl ester with area-percent purity above 99.5% by HPLC-UV at 214 nm. Residual solvent testing follows Ph. Eur. 2.4.24, and in-process control documentation follows ICH Q7 §7.2. The resulting derivative is filled into HDPE drums under nitrogen and used as a protected aspartate building block in Boc-chemistry solid-phase peptide synthesis; terminal product types include protected peptide resins and protected peptide fragments for therapeutic peptide APIs.

What Limits α-Selectivity in N-Boc-L-aspartic Anhydride Coupling to L-Phenylalanine Methyl Ester?

In the synthesis of the dipeptide sweetener L-α-aspartyl-L-phenylalanine methyl ester, BOC-L-aspartic acid is converted in situ to the N-Boc-L-aspartic anhydride because direct carbodiimide-mediated coupling of the free acid gives unacceptable β-aspartyl impurity. Acetic anhydride is charged at 1.2–1.5 mol equiv relative to BOC-L-aspartic acid in anhydrous dioxane, and the anhydride formation is held below 30 °C until FTIR anhydride carbonyl bands at 1860 cm⁻¹ and 1790 cm⁻¹ stabilise. The anhydride solution is then cooled to -5 °C to 0 °C before a pre-neutralised solution of L-phenylalanine methyl ester (1.0–1.05 mol equiv, triethylamine 1.0–1.05 mol equiv) is added over 60–90 min. Under these conditions the α-carbonyl opening dominates, but the β-isomer is not completely eliminated; fractional crystallisation from water/methanol is required to reduce the β-aspartyl impurity below 0.3% w/w for food-grade specifications. The protected dipeptide is deprotected under acidic conditions appropriate to the specific N-Boc route, and the final product is tested against the JECFA sweetener monograph, FCC, and EU Regulation 1129/2011; residual solvent limits are assessed by Ph. Eur. 2.4.24. Terminal finished product types include high-intensity sweetener for tabletop and beverage applications.

In anhydrous peptide conjugate manufacturing, activation of the α-carboxyl of BOC-L-aspartic acid as the N-hydroxysuccinimide ester precedes coupling to amine-functionalised polyethylene glycols, peptide dendrimers, or linker intermediates. The reaction is run in dimethylformamide at 10–15% w/v solids; BOC-L-aspartic acid is charged at 1.0 mol equiv, N-hydroxysuccinimide at 1.0–1.05 mol equiv, and N,N′-dicyclohexylcarbodiimide at 1.05–1.15 mol equiv. The activator is added over 30–45 min at 0–5 °C because the unprotected β-carboxyl can form oligoesters if the temperature exceeds 8 °C or if reaction time exceeds 14 h. After dicyclohexylurea filtration, the filtrate is concentrated to 30–40% solids and precipitated into cold methyl tert-butyl ether; the isolated N-Boc-L-aspartic acid α-NHS ester is dried at 25 °C under 50 mbar for 12 h and stored at -20 °C over 0.3 nm molecular sieves. Moisture uptake above 0.3% w/w hydrolyzes the active ester, and batch release includes quantitative ¹H NMR at 400 MHz for active ester content and LC-MS for Boc-protected impurity profiling. Compliance standards include ICH Q7 §12.1 for starting-material specifications, REACH 1907/2006 for industrial use in the EU, and ICH M7 for mutagenic impurity control with a purge factor above 1000 for dicyclohexylcarbodiimide. Terminal finished product types include N-protected aspartic acid active esters supplied to peptide-polymer conjugate manufacturing, diagnostic peptide synthesis, and antibody-linker intermediate production.

ADC Linker Fragment Construction With Unprotected β-Carboxyl Handling Controls

For targeted oncology linker-payload intermediates, BOC-L-aspartic acid is used as the C-terminal or internal aspartate residue in a solution-phase peptide-linker fragment because the free β-carboxyl can be converted to a hydrazide or amide after α-coupling. Coupling is performed in dimethylformamide at 0–5 °C using BOC-L-aspartic acid (1.0 mol equiv), HATU (1.05–1.10 mol equiv), and N,N-diisopropylethylamine (2.0–2.5 mol equiv); after 15 min the batch is warmed to 20 °C and held for 2–4 h, at which point conversion is checked by UPLC-MS and additional HATU (0.05 mol equiv) is added only if free amine remains above 1.0% area. Preparative HPLC then separates the target fragment from the β-coupled branched impurity using a C18 column with acetonitrile/water containing 0.1% v/v trifluoroacetic acid and a gradient from 10% to 60% acetonitrile over 35 min. Lyophilisation at -40 °C and 0.02 mbar produces a trifluoroacetate salt that is stored under argon at -20 °C. Quality standards for the linker intermediate include ICH Q3D elemental impurity testing by ICP-MS per USP 233, ICH M7 assessment for genotoxic impurities, and residual solvent analysis by Ph. Eur. 2.4.24. Terminal finished product types are peptide-linker intermediates for subsequent conjugation to cytotoxic payloads in antibody-drug conjugates and peptide-drug conjugates.

When Oligopeptide Synthesis Targets Leave-on Cosmetic Actives, Lyophilisation Parameters Influence Residual Acid Content

In the preparation of synthetic oligopeptides for anti-aging skin care, BOC-L-aspartic acid is introduced via solution-phase fragment coupling rather than as a direct cosmetic ingredient. The coupling stoichiometry is BOC-L-aspartic acid 1.0–1.2 mol equiv relative to the resin-free growing peptide amine, with HOBt monohydrate 1.1–1.3 mol equiv and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 1.1–1.3 mol equiv in ethyl acetate/dimethylformamide 4:1 v/v at 0–10 °C. The free β-carboxyl is retained to provide anionic character in the final oligopeptide, but residual trifluoroacetic acid from final Boc cleavage must be controlled because acidic actives shift the pH of leave-on formulas below the acceptable range. Lyophilisation is conducted at -50 °C and 0.01–0.05 mbar for 48 h, followed by ion-pair HPLC against a standard to confirm residual TFA below 0.1% w/w. Compliance for the finished cosmetic active includes EU Cosmetic Regulation 1223/2009 Annex II for prohibited substances and Article 10 safety assessment, ISO 22716:2007 for GMP, and REACH 1907/2006 for substance registration. In the final leave-on serum, the oligopeptide active is used at 0.0001–0.05% w/w (1–500 ppm) depending on the specific peptide sequence; the BOC-L-aspartic acid raw material is not present in the marketed formulation. Terminal finished product types include anti-aging facial serums, eye creams, and peptide-enriched moisturizers.

Poly(β-benzyl L-aspartate) NCA Polymerisation Windows and Initiator Stoichiometry

Conversion of BOC-L-aspartic acid to β-benzyl L-aspartate N-carboxyanhydride proceeds through β-esterification, Boc removal with trifluoroacetic acid in dichloromethane, and cyclization with triphosgene at 0.35–0.40 mol equiv in anhydrous tetrahydrofuran at 40–50 °C. The crude NCA is recrystallized from ethyl acetate/n-hexane until chloride content by ion chromatography is below 50 ppm and NCA purity by FTIR shows the characteristic double carbonyl bands at 1850 cm⁻¹ and 1785 cm⁻¹. Ring-opening polymerization is initiated with n-hexylamine at a monomer-to-initiator ratio of 20:1 to 200:1, producing number-average molecular weights from approximately 4,000 Da to 42,000 Da in dimethylformamide at 25 °C under nitrogen for 72 h. The polymerization is terminated by precipitation into cold diethyl ether, and residual NCA monomer is controlled by GPC-RID below 0.5% w/w. Published pilot-scale data for narrow-dispersity BOC-L-aspartic acid-derived NCA polymerisation in stainless steel reactors is limited; glass-lined equipment is preferred because chloride contamination shifts the polymer polydispersity. Compliance for the resulting poly(β-benzyl L-aspartate) when intended as a drug carrier includes ISO 10993-5 for cytotoxicity, ISO 10993-12 for extractables testing, and USP 661.1 for plastic components if the polymer is used in a primary container. Terminal finished product types include poly(β-benzyl L-aspartate) homopolymers and block copolymers for micellar drug delivery, tissue-engineering scaffolds, and controlled-release implants.